Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
April W. Armstrong

April W. Armstrong

Dermatology clinical investigator and academic dermatologist

Appears in 1 story

Notable Quotes

"Sotyktu is a welcome first-line systemic treatment option." — April Armstrong, BMS statement (context: TYK2 class arrival)

Stories

Takeda’s once–daily psoriasis pill just hit phase 3: a real shot at biologic–level skin clearance

New Capabilities

Published/investigator on TYK2 oral trial programs

Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don't. Takeda's once-daily TYK2 pill zasocitinib just cleared Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).

Updated Yesterday